경구용 직접 항응고제(DOAC) 시장 : 시장 예측(2026-2032년)

The Direct Oral Anticoagulants Market is projected to grow by USD 64.58 billion at a CAGR of 8.76% by 2032.

Direct Oral Anticoagulants: Executive Overview

Direct oral anticoagulants (DOACs) are prescription medicines used primarily to prevent and treat thromboembolic conditions, including stroke prevention in non-valvular atrial fibrillation and treatment or prevention of venous thromboembolism. Their clinical use is shaped by dosing convenience, predictable pharmacology, oral administration, renal function, bleeding risk, drug interactions, and the availability of reversal strategies. Adoption also depends on diagnosis rates, guideline alignment, reimbursement, prescriber familiarity, and patient access to follow-up care.

Clinical Practice Is Shifting Toward Simpler, Risk-Aware Anticoagulation

The landscape is moving from routine reliance on vitamin K antagonists toward more individualized anticoagulation pathways. DOACs generally avoid regular coagulation-monitoring requirements, which can reduce treatment burden, while patient selection remains essential because renal impairment, extremes of body weight, liver disease, active bleeding, interacting medicines, and adherence challenges affect suitability. Clinical practice is also placing greater emphasis on shared decision-making, perioperative management, medication reconciliation, and rapid recognition of bleeding or thrombotic complications.

Artificial Intelligence Strengthens Risk Assessment and Care Coordination

Artificial intelligence can support DOAC care by identifying patients with atrial fibrillation or venous thromboembolism in electronic records, flagging contraindications, detecting potentially unsafe combinations, and prioritizing follow-up for missed refills or abnormal renal-function results. Natural-language processing may help extract bleeding history and medication information from clinical notes, while predictive tools can assist risk stratification. These applications require clinically validated datasets, transparent outputs, privacy safeguards, bias monitoring, and human oversight; AI should support prescribing decisions rather than replace them.

Regional Insights: Uneven Access and Different Care Pathways

North America combines broad clinical familiarity with strong specialist infrastructure, but affordability, insurance design, and continuity of primary care influence access. Europe benefits from guideline-driven practice and established health systems, while national reimbursement and prescribing policies differ. Asia-Pacific spans advanced urban systems and settings where diagnosis, specialist availability, and medicine access remain uneven. Latin America continues to balance growing cardiovascular-care needs with budget constraints and fragmented access. In the Middle East, expanding hospital capacity coexists with variation in reimbursement and clinical resources. Africa faces substantial gaps in screening, diagnosis, anticoagulation access, laboratory and pharmacy infrastructure, and long-term follow-up.

Group Insights: Policy Alignment Shapes Uptake and Safety

ASEAN countries show substantial diversity in healthcare financing, regulatory maturity, and access between metropolitan and rural populations. BRICS members face differing burdens of atrial fibrillation, venous thromboembolism, and healthcare inequality, making local affordability and supply continuity important. The European Union benefits from shared scientific and regulatory frameworks but retains national differences in reimbursement and implementation. G7 health systems generally have mature diagnostic and pharmacovigilance capabilities, while aging populations increase demand for careful anticoagulation management. GCC states often have well-developed urban hospitals but must address variation in referral pathways, local clinical capacity, and population mobility. NATO members operate across diverse health systems, with resilience, procurement continuity, and care access relevant to anticoagulant availability.

Country Insights: Priorities Differ Across Major Health Systems

Australia emphasizes coordinated chronic-disease care and rural access. Brazil must address geographic inequality and continuity across public and private services. Canada faces distance-related access challenges alongside established clinical infrastructure. China is expanding cardiovascular diagnosis and treatment capacity while managing regional variation. France, Germany, Italy, and Spain operate within mature European systems, with attention to reimbursement, prescribing quality, aging populations, and integrated follow-up. India's priorities include affordability, diagnosis, and access beyond major cities. Japan and South Korea combine advanced healthcare delivery with rapidly aging populations and a need for careful dose and interaction management. Mexico continues to strengthen cardiovascular care amid uneven access. Russia's landscape is influenced by regional healthcare variation and supply continuity. The United Kingdom relies on guideline-based pathways while addressing service capacity and health inequalities. The United States has extensive clinical adoption but significant affordability, insurance, and care-coordination considerations.

Industry Priorities: Build Safe, Accessible, Data-Informed Care

Industry leaders should align clinical education with evidence-based patient selection, renal-dose assessment, interaction screening, adherence support, and perioperative guidance. Access strategies should account for reimbursement differences, generic and branded availability, patient assistance needs, and rural distribution. Partnerships with health systems can improve medication reconciliation, follow-up, and rapid management of bleeding events. Digital tools should focus on validated clinical workflows, explainable alerts, secure data practices, and measurable outcomes. Leaders should also strengthen pharmacovigilance, monitor real-world safety across demographic groups, and support appropriate use rather than indiscriminate treatment expansion.

Research Methodology: Evidence-Based Market Assessment

This executive summary uses a structured review of authoritative clinical guidelines, regulatory information, peer-reviewed literature, public-health evidence, and health-system publications relevant to DOAC use. The analysis organizes findings by clinical practice, technology, geography, economic access, and healthcare-system readiness. Regional, group, and country perspectives are synthesized from documented differences in disease burden, diagnostic capacity, reimbursement, regulation, and care delivery. Conclusions are qualitative and deliberately exclude market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims.

Conclusion: Responsible Expansion Depends on Patient-Centered Systems

DOACs have become an important component of contemporary anticoagulation because they can simplify treatment for appropriately selected patients. Their benefits depend on accurate diagnosis, individualized dosing, adherence, interaction management, renal and hepatic assessment, and timely response to bleeding or thrombosis. The next phase of progress will be determined less by medicine availability alone than by equitable access, integrated follow-up, validated digital support, and consistent implementation of safe prescribing practices across diverse health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Direct Oral Anticoagulants Market, by Molecule

• 7.1. Introduction
• 7.2. Apixaban
• 7.3. Dabigatran
• 7.4. Edoxaban
• 7.5. Rivaroxaban

8. Direct Oral Anticoagulants Market, by Mechanism Of Action

• 8.1. Introduction
• 8.2. Direct Thrombin Inhibitor
• 8.3. Factor Xa Inhibitor

9. Direct Oral Anticoagulants Market, by Indication

• 9.1. Introduction
• 9.2. Stroke Prevention In Atrial Fibrillation
• 9.3. Venous Thromboembolism Prevention
  • 9.3.1. Medical Patients
  • 9.3.2. Orthopedic Surgery
    • 9.3.2.1. Hip Replacement
    • 9.3.2.2. Knee Replacement
• 9.4. Venous Thromboembolism Treatment
  • 9.4.1. Deep Vein Thrombosis
  • 9.4.2. Pulmonary Embolism

10. Direct Oral Anticoagulants Market, by Route Of Administration

• 10.1. Introduction
• 10.2. Capsule
• 10.3. Tablet

11. Direct Oral Anticoagulants Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Home Healthcare
• 11.4. Hospitals

12. Direct Oral Anticoagulants Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacy
• 12.3. Online Pharmacy
• 12.4. Retail Pharmacy

13. Direct Oral Anticoagulants Market, by Region

• 13.1. Introduction
• 13.2. Europe
• 13.3. Asia-Pacific
• 13.4. North America
• 13.5. Latin America
• 13.6. Middle East
• 13.7. Africa

14. Direct Oral Anticoagulants Market, by Group

• 14.1. Introduction
• 14.2. NATO
• 14.3. G7
• 14.4. European Union
• 14.5. BRICS
• 14.6. ASEAN
• 14.7. GCC

15. Direct Oral Anticoagulants Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Germany
• 15.4. China
• 15.5. Japan
• 15.6. United Kingdom
• 15.7. France
• 15.8. India
• 15.9. Canada
• 15.10. Italy
• 15.11. Australia
• 15.12. Spain
• 15.13. Brazil
• 15.14. South Korea
• 15.15. Mexico
• 15.16. Russia

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Bristol-Myers Squibb Company
• 17.2. Pfizer Inc.
• 17.3. Bayer AG
• 17.4. Johnson & Johnson Services, inc.
• 17.5. Daiichi Sankyo Company, Limited
• 17.6. Sandoz International GmbH
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Aarti Pharmalabs Limited
• 17.9. Alembic Pharmaceuticals Limited
• 17.10. Apotex Inc.
• 17.11. Dr. Reddy's Laboratories Limited
• 17.12. Lupin Limited
• 17.13. Merck & Co., Inc.
• 17.14. MSN Laboratories Private Limited
• 17.15. Novartis AG
• 17.16. Polpharma SA
• 17.17. Tiefenbacher Group
• 17.18. Torrent Pharmaceuticals Ltd

18. Key Experts